GlobeNewswire by notified

Resolutions from the annual shareholders’ meeting 2024

30.4.2024 18:02:02 CEST | GlobeNewswire by notified

Share


Today an ordinary shareholders’ meeting was conducted. The following resolutions were made:

•  Approval of the audited Annual Report for 2023

•  Approval of distribution of profit with payment of an ordinary dividend of DKK 2.00 or EUR 0.27 per A/B share of DKK 2 for the last four months (September 1 - December 31) of 2023. Legacy Novozymes shareholders will then have received a total pay-out of the 2023 adjusted net profit of DKK 6.20 per share, which equals an increase of 3% compared with 2022.

•  Approval of the Remuneration Report for 2023

•  Approval of the remuneration of members of the Board of Directors

•  Re-election of Cornelis (Cees) de Jong as Chair and Jesper Brandgaard as Vice Chair of the Board of Directors

•  Re-election of Heine Dalsgaard, Sharon James, Kasim Kutay, Lise Kaae, Kevin Lane, Morten Sommer and Kim Stratton as members of the Board of Directors

•  Election of EY Godkendt Revisionspartnerselskab as the company’s auditors in respect of statutory financial and sustainability reporting

•  Approval to renew authorizations to the Board of Directors to implement capital increases

•  Approval to renew the authorization to the Board of Directors to acquire treasury shares

•  Approval of authorization to the Board of Directors to distribute extraordinary dividends

•  Approval of amendments to the Articles of Association

•  Approval of amendments to the Remuneration Policy



Following the annual shareholders’ meeting, the Board of Directors consists of the following members:

•  Cornelis (Cees) de Jong, Chair

•  Jesper Brandgaard, Vice Chair

•  Heine Dalsgaard

•  Sharon James

•  Kasim Kutay

•  Lise Kaae

•  Kevin Lane

•  Morten Sommer

•  Kim Stratton



Employee representatives:

•  Anne Breum

•  Anders Hentze Knudsen

•  Preben Nielsen

•  Jens Øbro

•  Karen Louise Lauesen, observer

•  Kim Ib Sørensen, observer



For further information on members of the Board of Directors, please go to www.novonesis.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Duck Creek Technologies Highlights Esteemed Sponsors of Formation '2421.5.2024 14:30:00 CEST | Press release

Formation ‘24 - The Pinnacle Gathering of Global Insurance and Technology Innovators – Features Dozens of Industry Sponsors. BOSTON, May 21, 2024 (GLOBE NEWSWIRE) -- Duck Creek Technologies, the intelligent solutions provider defining the future of property and casualty (P&C) and general insurance, is thrilled to unveil the prominent sponsors set to join the forefront of insurance technology decision-makers at its highly anticipated customer conference, Formation ’24. The event is scheduled to take place from May 21 to May 23, 2024, at the Omni Dallas Hotel in Dallas, Texas. Duck Creek is poised to welcome insurtech leaders and industry professionals from around the world, fostering a dynamic environment with abundant educational and networking prospects centered on the latest trends and innovations driving the insurance industry forward. “This year we have record sponsorship commitments from over 60 members of our partner ecosystem, including platinum sponsors Aggne Global, Coforge, C

Ketabon To Present Advancements In At-Home Ketamine Therapy For Treatment-Resistant Depression At American Society Of Clinical Psychopharmacology Annual Meeting21.5.2024 14:30:00 CEST | Press release

Presentations Will Address Phase 2 Trial Success With Lead Asset KET01 And Comparative Study With Intranasal SPRAVATO® MUNICH, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today the Company will present poster presentations at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting taking place on May 28-31, 2024 at Miami Beach. Dr. Hans Eriksson, Chief Medical Officer of Ketabon and HMNC Brain Health, will elucidate details on topline results of its Phase 2 trial with KET01, an oral ketamine treatment with minimal side effects, showing rapid improvements in depression severity and Ketabon’s comparative study between KET01 and intranasal SPRAVATO®, the current FDA-approved ketamine formulation. Presentation details are as follows: Session: W16 Poster: Comparison of Tolerability, Safety, and Pharmacokinetics of Antidepressant Doses of Oral Ketamine Prolonged

HiddenA line styled icon from Orion Icon Library.Eye